Bitcoin ETFs attracted $304.73 million in inflows last week, reversing the previous week's $229 million outflows, driven mainly by Blackrock's IBIT fund with $675.96 million inflows. Despite a late-week sell-off, the overall inflow signals renewed institutional interest in Bitcoin. Ether ETFs continued to face outflows for the fourth week, losing $220.60 million, while altcoins like Zcash showed strong rebounds with $41.09 million inflows. The mixed flow patterns suggest cautious but growing confidence in Bitcoin, while Ether and some altcoins remain under pressure.
The story about Blackrock's $305 million Bitcoin ETF comeback provides context for cryptocurrency market activity on Pluang. For readers following crypto, here is Pluang's market snapshot as of Oct 26, 2026 18:21 WIB: out of 50 major cryptocurrencies, 26 rose and 23 fell today. Among notable movers, UNI gained 4.45% with 89% buy orders, contrasting with BAT which dropped 6.24% and had 84% sell orders, while CAKE rose 2.56% despite 94% sell orders. Typical hold times ranged from 65 to 93 days across these assets.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
